中国肺癌杂志2016，Vol.19Issue(8)：496-500,5.DOI:10.3779/j.issn.1009-3419.2016.08.02
EGFR-TKI治疗非小细胞肺癌中枢神经系统转移的进展
Research Progress of EGFR-TKI Therapy for Patients with Central Nervous System Metastases from Non-small Cell Lung Cancer
金英华 1信涛1
作者信息
- 1. 150001哈尔滨，哈尔滨医科大学附属第二医院
- 折叠
摘要
Abstract
Approximately half of all patients with non-small cell lung cancer (NSCLC) develop central nervous system metastases during the course of their disease which indicate poor prognosis. A part of NSCLC patients demonstrates activating epidermal growth factor receptor gene (EGFR) mutations who represent effectiveness and well tolerance of EGFR-specific tyrosine kinase inhibitors (TKIs) therapy. Although the systemic effcacy of targeted agents is established, the effcacy of central nervous system (CNS) metastases is not as well characterized. In this article, we review recent data on the use of EGFR inhibitors for treatment of patients with NSCLC and CNS metastases.关键词
肺肿瘤/表皮生长因子受体/EGFR-TKIs/中枢神经系统转移Key words
Lung neoplasms/Epidermal growth factor receptor/EGFR-tyrosine kinase inhibitors/Central nervous system metastases引用本文复制引用
金英华,信涛..EGFR-TKI治疗非小细胞肺癌中枢神经系统转移的进展[J].中国肺癌杂志,2016,19(8):496-500,5.
